Xarelto Sales Data

Rank 40 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Xarelto U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 40 (10) 18.72% 15.58%
Q3 2013 50 (21) 25.74% 21.88%
Q2 2013 71 ()

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
June 20, 2013FDA Sends Letter to J&J Over Xarelto DTC Ad
July 9, 2012U.S. FDA Grants Priority Review for Xarelto (rivaroxaban) Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PE
January 9, 2012NICE Needs More Evidence on New Treatment for People with Common Heart Condition
November 13, 2011Blood Thinner Xarelto Shows Promise for Heart Patients
November 4, 2011Xarelto Approved to Prevent Stroke in People With Abnormal Heartbeat
September 8, 2011FDA Advisers Review Clot Drug
August 29, 2011Ahead of the Bell: Blood Thinner Study Impresses
August 10, 2011Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat
July 24, 2011Anti-Clotting Drug May Cause Severe Bleeding With No Benefit
December 4, 2010New Blood Thinner May Help Fight Dangerous Leg Clots
Hide
(web1)